Skip to main content
main-content

The independent medical news service

Kidney cancer

23-10-2020 | Oncology | News | Article

Cabozantinib improves quality-adjusted survival in advanced RCC

Treatment with cabozantinib gives patients with advanced renal cell carcinoma significantly more time without disease progression and toxicity relative to treatment with sunitinib, CABOSUN trial data show.

07-10-2020 | Oncology | News | Article

Update adds support for HIF-2α inhibitor in VHL-associated RCC

A phase 2 trial update for hypoxia-inducible factor-2α inhibitor MK-6482 in patients with treatment-naïve renal cell carcinoma associated with von Hippel-Lindau disease has been presented at the ESMO Virtual Congress 2020.

02-10-2020 | Oncology | News | Article

Cabozantinib–atezolizumab has ‘encouraging activity’ in advanced RCC

Previously untreated patients with advanced clear cell renal cell carcinoma benefit from treatment with cabozantinib plus atezolizumab, suggest COSMIC-21 data.

21-09-2020 | Oncology | News | Article

Nivolumab–cabozantinib ‘a potential first-line option’ for advanced RCC

The phase 3 CheckMate 9ER trial has demonstrated significantly improved outcomes with the combination of nivolumab and cabozantinib versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma.

26-08-2020 | Oncology | News | Article

Gut microbiome linked to RCC immunotherapy efficacy

Research has demonstrated an association between the gut microbiome composition and response to treatment with immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.

14-08-2020 | Oncology | News | Article

Meta-analysis confirms ICI benefit for sarcomatoid RCC

Results from a meta-analysis support use of immune checkpoint inhibitors for the treatment of sarcomatoid renal cell carcinoma.

14-07-2020 | Oncology | News | Article

Data support post-ICI cabozantinib use in metastatic clear cell RCC

Real-world study data show that a high proportion of patients with metastatic clear cell renal cell carcinoma gain clinical benefit from treatment with cabozantinib following progression with immune checkpoint inhibitors.

03-07-2020 | Oncology | News | Article

Potential for anticancer, COVID-19 drug interactions highlighted

A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.

30-06-2020 | Oncology | News | Article

Salvage nivolumab–ipilimumab shows potential for some metastatic RCC patients

The combination of nivolumab and ipilimumab demonstrates antitumor activity and acceptable toxicity in patients with metastatic renal cell carcinoma previously exposed to PD-1 or PD-L1 inhibitors, say the authors of a chart review.

17-06-2020 | Oncology | News | Article

Immunotherapy de-escalation in advanced RCC not feasible yet

Results from two studies presented at the virtual 2020 ASCO Annual Meeting suggest that the strategy of using single-agent nivolumab followed by response-adaptive or salvage add-on ipilimumab cannot be recommended for patients with advanced renal cell carcinoma.

This independent news story was supported by an educational grant from Pfizer and Merck KGa

12-06-2020 | Oncology | News | Article

RCC studies identify biomarkers of PD-1 inhibitor outcomes

Analyses of the CheckMate 025 and KEYNOTE-427 trials of nivolumab and pembrolizumab, respectively, have identified biomarkers associated with response to the individual agents in patients with advanced renal cell carcinoma.

This independent news story was supported by an educational grant from Pfizer and Merck KGa

12-06-2020 | Oncology | News | Article

Second-line lenvatinib–pembrolizumab shows promise for metastatic ccRCC

Research suggests that patients with metastatic clear cell renal cell carcinoma with disease progression after immune checkpoint inhibitor therapy may benefit from the combination of lenvatinib and pembrolizumab.

This independent news story was supported by an educational grant from Pfizer and Merck KGa

09-06-2020 | Oncology | News | Article

KEYOTE-426 update ‘continues to support’ pembrolizumab plus axitinib

For patients with treatment-naïve advanced renal cell carcinoma, pembrolizumab plus axitinib offers superior overall survival to sunitinib, confirms an updated analysis from the KEYNOTE-426 trial.

This independent news story was supported by an educational grant from Pfizer and Merck KGaA

04-06-2020 | Oncology | News | Article

HIF-2α inhibition ‘promising’ for von Hippel–Lindau disease-associated RCC

Findings from an open-label phase 2 study suggest the first-in-class HIF-2α inhibitor MK-6482 has “promising efficacy and tolerability” in the treatment of renal cell carcinoma associated with von Hippel–Lindau disease.

08-04-2020 | Oncology | News | Article

Tocilizumab shows promise for COVID-19 treatment in people with cancer

The interleukin-6 receptor inhibitor tocilizumab warrants further investigation for the treatment of COVID-19 in patients with cancer, say the authors of a case report.

02-03-2020 | Oncology | News | Article

Cytoreductive nephrectomy ‘still plays a role’ for metastatic RCC

Cytoreductive nephrectomy continues to offer a significant overall survival benefit for carefully selected patients with metastatic renal cell carcinoma in the era of immune checkpoint inhibitor and targeted therapies, a propensity score-based analysis indicates.

This independent news story was supported by an educational grant from Pfizer and Merck KGaA

02-03-2020 | Oncology | News | Article

Updated CheckMate 214 analysis confirms nivolumab–ipilimumab RCC benefit

CheckMate 214 data presented at the 2020 Genitourinary Cancers Symposium show the continued benefit of combination treatment with nivolumab plus ipilimumab over sunitinib in individuals with treatment-naïve advanced renal cell carcinoma.

This independent news story was supported by an educational grant from Pfizer and Merck KGaA

28-02-2020 | Oncology | News | Article

Drug targeting HIF-2α ‘well-tolerated’ in advanced clear-cell RCC

MK-6482, a first-in-class hypoxia-inducible factor-2α inhibitor, has a favorable safety profile and demonstrates clinical activity in patients with advanced clear-cell renal cell carcinoma, phase 1/2 trial data suggest.

27-02-2020 | Oncology | News | Article

Sitravatinib may boost nivolumab efficacy in advanced clear-cell RCC

Adding sitravatinib to nivolumab results in a higher response rate and longer disease control in patients with advanced clear-cell renal cell carcinoma than has historically been achieved with nivolumab monotherapy, with no unacceptable toxicity, research shows.

21-02-2020 | Oncology | News | Article

Durvalumab–savolitinib duo has potential in metastatic papillary renal cell carcinoma

Patients with metastatic papillary renal cell carcinoma are likely to benefit from the durvalumab–savolitinib combination, show findings from the 1-year follow-up of the CALYPSO trial.

This independent news story was supported by an educational grant from Pfizer and Merck KGaA

Image Credits